Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
administered, allocated, allocation, analyze, assuming, began, big, brand, buying, channel, chronic, clear, collectability, collection, comfortable, consideration, constrained, contractual, convince, credit, customer, damaged, decreased, deliver, delivered, delivery, disease, distinct, dog, dose, dosing, doubtful, engineered, enhanced, entitled, exceeded, expansion, extent, forecasted, frequency, goal, handling, high, impaired, inbound, increasingly, individual, induced, Inflammatix, inflammatory, intent, intention, inventory, ISO, itching, judgment, kidney, labor, landlord, larger, long, modify, moving, national, network, older, opening, optimized, order, ordered, overhead, party, penetration, PK, placement, point, policy, preliminary, prior, prolonged, promised, promising, protein, published, rapidly, reduction, regional, regular, reinspection, relevant, resell, response, return, returned, reversal, score, single, size, skin, solution, statutory, strong, substance, suggest, sustained, therapeutic, therapy, Trademark, ultimately, uncover, workforce, write
Removed:
accrual, collaboration, initiated, metabolic, post, prepare, realization, recoverability, site, syndrome, Web
Filing tables
Filing exhibits
Related press release
Associated KIN transcripts
KIN similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Kindred Biosciences, Inc. (the “Company”) hereby certifies that, to his or her knowledge:
(i) The quarterly report on Form 10-Q for the period ended September 30, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: November 7, 2018 | By: /s/ Richard Chin | By: /s/ Wendy Wee |
| Name: Richard Chin, MD | Name: Wendy Wee | |
| Title: Chief Executive Officer | Title: Chief Financial Officer | |
| (Principal Executive Officer) | (Principal Financial and Accounting Officer) | |